Abstract
This article describes recent advances in the development and biological evaluation of small molecule mGluR4 positive allosteric modulators (PAMs), and, to a lesser extent, orthosteric agonists. Due to its expression in the basal ganglia, the Family 3 GPCR metabotropic glutamate receptor subtype 4 (mGluR4) has recently garnered a great deal of attention as a putative target for the treatment of Parkinsons disease and a variety of other CNS disorders. Until 2008, with the exception of the prototypical mGluR4 PAM ( – )-PHCCC, very few small molecule tools existed to probe the role of selective activation of mGluR4. This review will focus on the explosion of novel mGluR4 PAMs reported in the past year and the further preclinical validation of mGluR4 activation as a potentially groundbreaking treatment for Parkinsons disease.
Keywords: Metabotropic, mGluR4, Parkinson's disease, allosteric, positive allosteric modulator, dopamine, PHCCC, glutamate
Current Topics in Medicinal Chemistry
Title: Recent Progress in the Development of mGluR4 Positive Allosteric Modulators for the Treatment of Parkinsons Disease
Volume: 9 Issue: 10
Author(s): Craig W. Lindsley, Colleen M. Niswender, Darren W. Engers and Corey R. Hopkins
Affiliation:
Keywords: Metabotropic, mGluR4, Parkinson's disease, allosteric, positive allosteric modulator, dopamine, PHCCC, glutamate
Abstract: This article describes recent advances in the development and biological evaluation of small molecule mGluR4 positive allosteric modulators (PAMs), and, to a lesser extent, orthosteric agonists. Due to its expression in the basal ganglia, the Family 3 GPCR metabotropic glutamate receptor subtype 4 (mGluR4) has recently garnered a great deal of attention as a putative target for the treatment of Parkinsons disease and a variety of other CNS disorders. Until 2008, with the exception of the prototypical mGluR4 PAM ( – )-PHCCC, very few small molecule tools existed to probe the role of selective activation of mGluR4. This review will focus on the explosion of novel mGluR4 PAMs reported in the past year and the further preclinical validation of mGluR4 activation as a potentially groundbreaking treatment for Parkinsons disease.
Export Options
About this article
Cite this article as:
Lindsley W. Craig, Niswender M. Colleen, Engers W. Darren and Hopkins R. Corey, Recent Progress in the Development of mGluR4 Positive Allosteric Modulators for the Treatment of Parkinsons Disease, Current Topics in Medicinal Chemistry 2009; 9 (10) . https://dx.doi.org/10.2174/156802609789378272
DOI https://dx.doi.org/10.2174/156802609789378272 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functional Food with Some Health Benefits, So Called Superfood: A Review
Current Nutrition & Food Science Beyond The Therapeutic Effect of rTMS in Alzheimer’s Disease: A Possible Neuroprotective Role of Hippocampal BDNF? : A Minireview
Mini-Reviews in Medicinal Chemistry Training Psychiatrists in Cognitive Behavioral Psychotherapy: Current Status and Horizons
Current Psychiatry Reviews Management of Adverse Effects from Medications Used to Treat Substance Use Disorders
Current Psychopharmacology Current Burden of Hepatitis C Virus Infection Among Injecting Drug Users: A Mini Systematic Review of Prevalence Studies
Infectious Disorders - Drug Targets Editorial: Corticotropin Releasing Factor (CRF) and its Receptors: From Structure to Function in Health and Disease (Part I)
Current Molecular Pharmacology The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory
Current Pharmaceutical Design Brain Injury Associated with Widely Abused Amphetamines: Neuroinflammation, Neurogenesis and Blood-Brain Barrier
Current Drug Abuse Reviews Impacts of Hyper-Homocysteinemia and White Matter Hyper-Intensity in Alzheimers Disease Patients with Normal Creatinine: An MRI-Based Study with Longitudinal Follow-up
Current Alzheimer Research Polypharmacology Approach Against Migraine with Aura and Brain Edema for the Development of an Efficient Inhibitor and its Analogues
Current Computer-Aided Drug Design Strategies to Overcome Drug Resistance of Receptor Tyrosine Kinaseaddicted Cancer Cells
Current Medicinal Chemistry Naturally Occurring and Synthetic Imidazoles: Their Chemistry and Their Biological Activities
Current Medicinal Chemistry N-Acetylserotonin vs Melatonin: In-Vitro Controlled Release from Hydrophilic Matrix Tablets
Letters in Drug Design & Discovery Common Pathological Mechanisms and Risk Factors for Alzheimer’s Disease and Type-2 Diabetes: Focus on Inflammation
Current Alzheimer Research Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls
Current Psychiatry Reviews Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Effects of Cholinesterase Inhibitors on the Activities and Protein Levels of Cholinesterases in the Cerebrospinal Fluid of Patients with Alzheimers Disease: A Review of Recent Clinical Studies
Current Alzheimer Research Amyloids, Aggregates and Neuronal Inclusions: Good or Bad News for Neurons?
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Pharmacological Interactions on Blood Pressure Control in Arterial Hypertension, An Issue not to be Overlooked
Cardiovascular & Hematological Disorders-Drug Targets Phosphodiesterase Type 5 Inhibitor Abuse: A Critical Review
Current Drug Abuse Reviews